Agenus Inc (AGEN) Stock Price, Quote & News

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 674 4400

Fax: 781 674 4200

Website: www.agenusbio.com

Address:

3 Forbes Road, Lexington, United States

neversurrender2024 Oct. 27 at 8:41 PM

$AGEN garos atm alive and well...years away from any approval folks....

0 · Reply

BillyBobBleach Oct. 27 at 5:27 PM

$AGEN Big partnership has got to be finalizing. Competition is at the doorstep and no Zydus deal closure.

2 · Reply

joechuck71 Oct. 27 at 5:22 PM

$AGEN Received additional questions of interest! wow

0 · Reply

joechuck71 Oct. 27 at 5:05 PM

$AGEN Believe it or not just got a reply from my god daughter that they will be looking this all over and will get back to me. Interesting!

0 · Reply

joechuck71 Oct. 27 at 3:08 PM

$AGEN Just sent My God Daughter who is a producer for documentary's films for TV , Netflix and prime the link to the short video from the stockholders meeting Augst 27 on YouTube. I told her as much as I could and how it needs world exposer to save lives. I can't guaranty anything and nothing happens fast in the film world, but I tried. I also emailed The Bill Gates Foundation sent them the video as well. It's time we all try to get the word out already you can't make everything in life about money doing the right thing and helping people in need will make you feel like a million bucks let's go!

2 · Reply

BiotechBagholder Oct. 27 at 1:01 PM

$AGEN Interesting ESMO recap by Leerink/Truist here. There's a discussion on MSS CRC starting at about the 20:00 mark. They also discuss the STELLAR-303 data and market opportunity for zanzalintinib a bit later. Summit is initiating a Phase 3 trial of ivonescimab (PD-1xanti-VEGF bispecific) in 1L MSS CRC. Incyte is initiating a registrational program for INCA33890, (TGFβR2×PD-1 bispecific) in 3L MSS CRC. https://www.bloomberg.com/professional/insights/webinar/post-esmo-wrap-with-leerink-partners-bi-replay/.

0 · Reply

LiquidThetaLEAPS Oct. 27 at 3:33 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AGEN Current Share Price: $4.14 Contracts: $AGEN January 15, 2027 $5 Calls Scale in: $1.52- $1.86 Scale out: $2.36-$3.04 Can Easily Capture: 60% ROI Blended DTE: 446 Days | Join Elites here: https://liquidtheta.com

0 · Reply

UltimoDaBaggie Oct. 26 at 7:12 PM

$AGEN Agree that adverse events with zanzalintinib is significant https://x.com/altaioncology/status/1982512948145684790?s=46

0 · Reply

Biotechguy21 Oct. 26 at 5:15 PM

$AGEN some never learn. 😂😂😂🤡🤡🤡

0 · Reply

LiquidThetaLEAPS Oct. 26 at 5:35 AM

0 · Reply

Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript

$Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025$

Oct 17, 2025, 8:00 AM EDT - 10 days ago

Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

Oct 16, 2025, 7:48 AM EDT - 11 days ago

Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights

$France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer$

Sep 9, 2025, 7:43 AM EDT - 6 weeks ago

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Sep 5, 2025, 8:52 AM EDT - 7 weeks ago

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 2:04 PM EDT - 2 months ago

Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)

Aug 26, 2025, 9:37 AM EDT - 2 months ago

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

Aug 19, 2025, 7:30 AM EDT - 2 months ago

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Aug 11, 2025, 7:30 AM EDT - 2 months ago

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Jul 31, 2025, 7:30 AM EDT - 3 months ago

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

$Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025$

Jul 25, 2025, 12:46 PM EDT - 3 months ago

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

$Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3$

Jul 7, 2025, 8:55 AM EDT - 4 months ago

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Jun 17, 2025, 7:30 AM EDT - 4 months ago

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Jun 10, 2025, 1:30 PM EDT - 4 months ago

Agenus Announces Virtual Annual Shareholders Meeting

Jun 4, 2025, 2:38 PM EDT - 5 months ago

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Jun 3, 2025, 7:00 AM EDT - 5 months ago

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

May 30, 2025, 7:30 AM EDT - 5 months ago

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

May 23, 2025, 3:09 PM EDT - 5 months ago

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

May 15, 2025, 10:40 AM EDT - 5 months ago

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 12, 2025, 2:46 PM EDT - 6 months ago

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 7:30 AM EDT - 6 months ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:20 AM EDT - 6 months ago

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

Apr 29, 2025, 7:30 AM EDT - 6 months ago

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Apr 28, 2025, 3:30 PM EDT - 6 months ago

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Apr 25, 2025, 1:05 PM EDT - 6 months ago

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Apr 23, 2025, 12:05 PM EDT - 6 months ago

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Mar 25, 2025, 4:40 PM EDT - 7 months ago

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Mar 19, 2025, 7:30 AM EDT - 7 months ago

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Mar 11, 2025, 10:39 AM EDT - 8 months ago

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:30 AM EDT - 8 months ago

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Feb 26, 2025, 4:48 PM EST - 8 months ago

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Feb 25, 2025, 2:30 PM EST - 8 months ago

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Feb 25, 2025, 8:26 AM EST - 8 months ago

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:33 AM EST - 8 months ago

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

Feb 23, 2025, 7:38 PM EST - 8 months ago

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 9 months ago

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

$Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas$

Jan 29, 2025, 12:37 PM EST - 9 months ago

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Jan 22, 2025, 2:48 PM EST - 9 months ago

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Dec 18, 2024, 7:30 AM EST - 11 months ago

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Dec 5, 2024, 7:30 AM EST - 11 months ago

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Nov 27, 2024, 8:15 AM EST - 11 months ago

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Nov 12, 2024, 10:41 AM EST - 1 year ago

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 1 year ago

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Nov 7, 2024, 10:00 AM EST - 1 year ago

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

Nov 5, 2024, 7:30 AM EST - 1 year ago

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

Nov 4, 2024, 11:00 AM EST - 1 year ago

November 5 Deadline: Agenus Inc Is Being Sued For Defrauding The Public And Affected Shareholders Are Urged To Contact The Schall Law Firm

neversurrender2024 Oct. 27 at 8:41 PM

$AGEN garos atm alive and well...years away from any approval folks....

0 · Reply

BillyBobBleach Oct. 27 at 5:27 PM

$AGEN Big partnership has got to be finalizing. Competition is at the doorstep and no Zydus deal closure.

2 · Reply

joechuck71 Oct. 27 at 5:22 PM

$AGEN Received additional questions of interest! wow

0 · Reply

joechuck71 Oct. 27 at 5:05 PM

$AGEN Believe it or not just got a reply from my god daughter that they will be looking this all over and will get back to me. Interesting!

0 · Reply

joechuck71 Oct. 27 at 3:08 PM

2 · Reply

BiotechBagholder Oct. 27 at 1:01 PM

0 · Reply

LiquidThetaLEAPS Oct. 27 at 3:33 AM

0 · Reply

UltimoDaBaggie Oct. 26 at 7:12 PM

$AGEN Agree that adverse events with zanzalintinib is significant https://x.com/altaioncology/status/1982512948145684790?s=46

0 · Reply

Biotechguy21 Oct. 26 at 5:15 PM

$AGEN some never learn. 😂😂😂🤡🤡🤡

0 · Reply

LiquidThetaLEAPS Oct. 26 at 5:35 AM

0 · Reply

joechuck71 Oct. 25 at 6:21 PM

$AGEN News coming lowest short interest in many years 10/15/2025 1,943,316 not many shorts left

1 · Reply

chrisdacs Oct. 25 at 1:37 AM

$AGEN this stupid is stock.

0 · Reply

Biotechguy21 Oct. 25 at 12:22 AM

$AGEN look who is back 👀 and this means look out below 😂😂

0 · Reply

Scooter0732 Oct. 24 at 8:36 PM

$AGEN The push continues https://dcjournal.com/fda-must-keep-up-with-science-on-cancer/

5 · Reply

Overcrumb Oct. 24 at 7:16 PM

$AGEN most stocks having a nice upside today. Agenus sinking again.

0 · Reply

2_logs_higher Oct. 24 at 5:40 PM

$AGEN & $INCY, $LLY INCY needs to buy needs to buy Agen LLY needs to buy INCY New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) https://finance.yahoo.com/news/lillys-baricitinib-delivered-near-complete-104500483.html?guccounter=1

1 · Reply

2_logs_higher Oct. 24 at 5:35 PM

$AGEN & $INCY INCY needs to buy Agenus! New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) https://finance.yahoo.com/news/lillys-baricitinib-delivered-near-complete-104500483.html?guccounter=1

0 · Reply

LiquidThetaOptions Oct. 24 at 3:13 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AGEN Current Share Price: $4.18 Contracts: $AGEN January 15, 2027 $5 Calls Scale in: $1.52- $1.86 Scale out: $2.36-$3.04 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

BakerBrother Oct. 24 at 2:08 PM

$AGEN Clear sailing ahead.

0 · Reply

BakerBrother Oct. 24 at 11:32 AM

$AGEN Three takeaways from Wednesday’s call: 1) We will get a neodjuvant trial sponsored by Agenus 2) Agenus has submitted the additional info requested by CFIUS, however, the 45 day clock from accepted has not begun. 3) We will see 2-year OS data for the MSS-CRC trial when data matures. The fact that responses are still ongoing is a +. What else did I miss?

3 · Reply

UltimoDaBaggie Oct. 23 at 9:07 PM

$AGEN Just read the Lancet paper on zanzalintinib. Response is not as good as bot/bal but its a phase 3 with hundreds of pts so cannot really compare. However, toxicity seems significant which is a game changer for 3rd line treatment Also read the final NICHE results in Nature. Only abstract. I dont have access to full text. Results are subpar to bot/bal Finally, read the ESMO abstract on regorafenib/bot/bal combo => Very few responses but bot dose was only 25 mg. For comparison, in our phase 2 dose was 75/150 mg. But still significant toxicity due to TKIs at that dose. My conclusion: 1. Bot/bal is still the best IO combo - at least for colorectal. 2. Combinations with TKIs will not work well, primarily 2/2 DLTs

1 · Reply

joechuck71 Oct. 23 at 6:18 PM

$AGEN "Zynext Ventures is heading to hashtag#BIO-Europe in Vienna!" Nov 2 and 3

0 · Reply

Market Cap	131.92M
Revenue (ttm)	103.46M
Net Income (ttm)	-227.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	6.91
Profit Margin	-219.61%
Debt to Equity Ratio	-0.10

Volume	196,300
Avg Vol	445,104
Day's Range	N/A - N/A
Shares Out	31.86M
Stochastic %K	40%
Beta	1.43
Analysts	Sell
Price Target	$12.33